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E-mail address: somlukc@swu.ac.th (S. ChuengsamAim: The purpose of this study is to determine the association between the components used to deﬁne
metabolic syndrome and cardiovascular risk using different criteria stratiﬁed by sex.
Methods: A cross-sectional study with 608 subjects enrolled at the out-patients department of the Thai
Internal Medicine Clinic was performed between October 2006 and September 2007. Included subjects
had metabolic syndrome as deﬁned by WHO, NCEP III, or IDF. The demographic and laboratory charac-
teristic of the subjects including BMI, waist circumference, waist/hip ratio, fasting blood glucose, 2 h
postprandial blood glucose, triglyceride, HDL, blood pressure, and microalbuminuria, were measured
and recorded by chart review. Cardiovascular risk was determined by pulse wave velocity. The sensitivity
and speciﬁcity of the component of metabolic syndrome according to the three criteria were stratiﬁed by
sex.
Results: The HDL sensitivity was higher in females than in males. Among the different component of met-
abolic syndrome, blood pressure gave the strongest association with cardiovascular risk, with odds ratios
of 13.6, 11.97, and 10.5 for the criteria of IDF, NCEP III, and WHO, respectively. Moreover, when analyzing
by sex, the odds ratio for female subjects were about two times higher than that of males. The rest of the
components in each of criteria exceptional HDL gave odds ratios of 2–4.
Conclusions: The appropriate components to predict cardiovascular risks are: high blood pressure and cut
off point of waist circumference in females, as deﬁned by the IDF criterion, and high triglyceride in males,
as deﬁned by the IDF criterion.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Metabolic syndrome (Mts) is deﬁned by a cluster of metabolic
risk factors including: central obesity, hypertension (HT), impaired
fasting glucose (IFG) or impaired glucose tolerance (IGT), diabetes
mellitus (DM), and dyslipidemia (DLD), which predispose an indi-
vidual to develop cardiovascular disease and type 2 diabetes [1–3].
Mts is important because recent advances in science and technol-
ogy have brought signiﬁcant changes to the environment, social
behaviour and lifestyle. Such transformations have resulted in an
increased risk of metabolic syndrome and cardiovascular diseases
[4–7]. Accordingly, the high prevalence of Mts around the world,
including Asia, has signiﬁcantly increased in association with a
number of the components currently used to diagnose Mts [8,9].ellitus. Published by Elsevier Ltd.
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OClinically, Mts can be deﬁned by different criteria such as that of
the National Cholesterol Educational Program Adult Treatment Pa-
nel (NCEP III) [10] and the International Diabetes Foundation (IDF)
[11], which differ slightly from the NCEP III in the cut off point of
waist circumference and the level of fasting blood glucose (FBG).
The WHO criterion [12], however, differs from the above criteria
in two components, impaired glucose tolerance (IGT) and positive
microalbuminuria (MAU). The original purpose to diagnose Mts by
each of these criteria was to identify important components of Mts
that relate to cardiovascular risk [13]. However, such metabolic
components have not been identiﬁed unequivocally. The present
study uses different criteria stratiﬁed sex to determine the associ-
ation between Mts components and cardiovascular risk.
2. Methods
We did a cross-sectional study to compare the components of
Mts according to different criteria of cardiovascular risks, and the
presence of metabolic components such as diabetes mellitus, IFG/
IGT, dyslipidemia and hypertension in 608 subjects recruited frompen access under CC BY-NC-ND license.
Table 1
Baseline characteristics of patients.
Characteristics Categories Number Percent
DM status DM 339 55.8
IFG/IGT 132 21.7
Normal FBS 137 22.5
Total 608 100
Sex Male 180 29.6
Female 428 70.4
Total 608 100
Smoking status Current smoking 33 5.4
Ex-smoking 60 9.9
Non-smoking 514 84.5
Total 607 99.8
Drinking status Current drinking 47 7.7
Ex-drinking 60 9.9
Non-drinking 500 82.2
Total 607 99.8
Aerobic exercise Active exercise 195 32.1
Non-active exercise 413 67.9
Total 608 100
Weight (Wt.) 68.02 ± 15.16
Height (Ht.) 1.58 ± 0.08
Body mass index (BMI) 27.08 ± 0.08
Waist circumference (WC) 90.94 ± 0.08
Hip circumference (HC) 99.89 ± 0.08
W–H ratio 0.91 ± 0.08
Table 2
Prevalence (percent) with 95% conﬁdence intervals of metabolic syndrome by sex.
Criteria Male Female Overall
NCEP III Prevalence 68.3 70.1 69.6
95% CI 61.5–75.1 65.8–74.3 65.9–73.3
n 180 428 608
WHO Prevalence 83.3 65.9 71.1
95%CI 77.9–88.7 61.4–70.4 67.5–74.7
n 180 428 608
IDF Prevalence 61.7 69.9 67.4
95% CI 54.6–68.8 65.6–74.2 63.7–71.1
n 179 428 607
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ulty of Medicine, Srinakharinwirot University. Mts was used as de-
ﬁned by WHO, NCEP III, and IDF criteria during October 2006 to
September 2007. The study protocol was approved by the Ethics
Committee of the faculty and informed consent was obtained from
all subjects participating in the study. We studied the demographic
and laboratory characteristic among subjects, including BMI, waist
circumference (WC), waist/hip ratio (W/H), fasting blood glucose
(FBG), 2 h postprandial blood glucose (IGT), triglyceride (TG),
HDL, blood pressure (BP), MAU and associated medication through
chart review. The data were cross-sectionally collected at the
beginning of 2006 and at the end of 2007, approximately
12 months apart. Active exercise was deﬁned by subjects engaging
in aerobic exercise more than 3 days per week and at least 15 min
per day.
The WHO criteria [12] consists of the identiﬁcation of insulin
resistance, e.g. type 2 diabetes or impaired fasting glucose (IFG)
or IGT, plus any two of the following: elevated blood pressure
(P140/90 mm Hg or drug therapy), plasma TGP 150 mg/dl, HDL
<35 mg/dl (men) or <40 mg/dl (women), BMI >30 kg/m2 and/or
W/H ratio >0.9 (men) or >0.85 (women), urinary albumin >20 g/
min; Alb/Cr >30 mg/g.
The NECP III [10] deﬁnes Mts by the presence of three or more
of the following risk determinants: central obesity [WC >100 cm
or, 40 inches (men); >88 cm or >35 inches (women)]; elevated
TG (P150 mg/dl), low HDL cholesterol (<40 mg/dl in men,
<50 mg/dl in women), HT (P130/85 mm/Hg), IFG (P110 mg/dl)
[13]. Subjects were deﬁned as Mts by IDF [11] if central obesity
was present, and any two of the following: elevated TG
(P150 mg/dl), low HDL cholesterol (<40 mg/dl in men, <50 mg/dl
in women), HT (P130/85 mm/Hg), IFG (P100 mg/dl). The
WCP 90 cm in men or P80 cm in women was deﬁned as central
obesity in Japanese Asian patients [11]. The WC was measured by a
tape in the direction of the horizontal plane, midway between the
inferior margin of the risk and the superior border of the iliac crest
[11,13,14].
Cardiovascular risk was determined by pulse wave velocity
(PWV) [15] measured by Colin Medical Technology (VP-1000),
and analyzed by pulse wave diagnosis results. Peripheral PWV
(ba PWV) represented as volume waveforms for the brachium
and ankle was measured using a VP-1000 pulse wave analyzer (Co-
lin Medical Technology), as previously described [16]. In brief, the
PWV measurement system recorded electrocardiogram, phonocar-
diogram and three pulse waves from the brachial and dorsalis
pedis arteries. Pressure pulse sensors were used to measure pulse
waves, and ampliﬁer, ﬁlter, and isolation circuits were used to de-
tect accurate signals. The intersecting tangent algorithm, using the
least square mean (LSM) method, was adapted to determine up-
stroke points. Regional PWV values, brachial and dorsalis pedis
were calculated automatically after collecting 10 s of data. For baP-
WV, brachial-dorsalis pedis transit time and PWV were calculated
from the brachial-dorsalis pedis path length divided by transit
time. Path length was estimated from the linear distance from
the sternal notch to the dorsalis pedis artery at the point of
applanation.
In a previous study, these analyses demonstrated that baPWV
equal to or over 1400 cm/s was an independent variable for assess-
ing risk stratiﬁcation. According to the Framingham score, and for
discriminating between patients with either stroke or coronary
heart disease in both genders although our study referred to a
cut off of baPWV equal to or over 1400 cm/s as a surrogate to arte-
rial stiffness and representative of cardiovascular risks.
Logistic regression was used to determine the association of the
components of Mts according to different criteria with of cardio-
vascular risk by measurement of PWV. Multivariate analyses were
performed to adjust for all components of metabolic syndrome inthe same criteria, including age, sex, LDL, cholesterol, and smoking.
The prevalence rate of Mts using the three criteria and also for each
component within each were calculated with 95% conﬁdence
intervals for males and females and overall. Sensitivity and speci-
ﬁcity for determining Mts for individual components were
computed using the respective criteria as gold standards and pre-
sented separately for both sexes. The results were considered sta-
tistically signiﬁcant if the p-value was less than 0.05 Data analyses
were performed using SPSS package for windows, version 11.3. Results
A total of 608 subjects were included in the study. About 56%
of them had been diagnosed with diabetes, 21.7% had IFG or IGT,
and the rest were normal. About 30% of the subjects were males.
Eighty ﬁve percent were non-smokers and 82% percent were
non-drinkers. Thirty two percent had regular exercise. Average
values for age, weight, body mass index, waist circumference,
and W–H ratio were 57.79, 68.02, 27.08, 90.94, and 0.91, respec-
tively (Table 1).
The overall prevalence rate (%) with 95% conﬁdence intervals of
metabolic syndrome in this population was found to be 69.6 (65.9–
73.3), 71.1 (67.5–74.7), and 67.4 (63.7–71.1), when using the crite-
ria of NCEP III, WHO, and IDF, respectively (Table 2).
80 S. Chuengsamarn et al. / International Journal of Diabetes Mellitus 2 (2010) 78–82Table 3 shows a prevalence of metabolic syndrome components
when using different criteria. The prevalence of Mts for positive
waist circumference was 73.4% in IDF criteria, but it was 46.1% in
NCEPT III, while the prevalence of Mts for positive BMI or W/H ra-
tio in WHO criteria was 79.8%. Subjects who had high triglyceride
were at 67.3% for WHO criteria, while only 63.2% for the other two
criteria. The prevalence rates of high blood glucose were 74.8%,
63.3%, and 77.5% for IDF, NCEP III, andWHO. The prevalence of high
blood pressure (HBP) was not only at a positive high level of 73.4%
in the both IDF and NCEPT III, but also at a positive high level in
WHO (73.2%).
Table 4 shows sensitivity and speciﬁcity for diagnosing meta-
bolic syndrome for each component of metabolic syndrome, using
the three criteria and stratiﬁed by sex. For HDL, sensitivity was
higher in females than males. The speciﬁcity of blood pressureTable 3
Prevalence (percent) of components of metabolic syndrome for IDF, NCEP III, and
WHO criteria.
Components of criteria Male Female All
IDF
Waist circumference 65.6 76.6 73.4
Triglyceride 64.4 62.6 63.2
HDL 49.4 77.8 69.4
Blood pressure 82.2 69.6 73.4
Fasting blood glucose 88.3 69.2 74.8
NCEP III
Waist circumference 26.1 54.4 46.1
Triglyceride 64.4 62.6 63.2
HDL 49.4 77.8 69.4
Blood pressure 82.2 69.6 73.4
Fasting blood glucose 76.7 57.7 63.3
WHO
Fasting blood glucose or IGT 88.9 72.7 77.5
BMI or W/H ratio 82.8 78.5 79.8
Triglyceride 68.3 66.8 67.3
Blood pressure 82.2 69.4 73.2
Microalbuminuria 53.9 46.5 48.7
Table 4
Sensitivity and speciﬁcity for diagnosing metabolic syndrome of components of
metabolic syndrome for IDF, NCEP III, and WHO criteria.
Components of
criteria
Sensitivity Speciﬁcity
Male
(%)
Female
(%)
Overall
(%)
Male
(%)
Female
(%)
Overall
(%)
IDF
Waist
circumference
100.0 100.0 100.0 89.7 77.5 81.7
Triglyceride 73.0 74.2 73.9 47.8 64.3 58.7
HDL 57.7 87.0 79.0% 62.7 43.4 50.0
Blood pressure 91.0 85.9 87.3 30.3 66.9 54.4
Fasting blood
glucose
100.0 82.6 87.3 30.9 62.0 51.3
NCEP III
Waist
circumference
35.8 71.3 61.0 94.7 85.2 88.1
Triglyceride 78.0 75.3 76.1 64.3 67.2 66.3
HDL 67.5 90.7 83.9 89.3 52.3 63.6
Blood pressure 97.6 91.3 93.1 50.9 81.3 71.9
Fasting blood
glucose
95.1 78.3 83.2 63.2 90.6 82.2
WHO
Fasting blood
glucose or IGT
100.0 100.0 100.0 66.7 80.1 77.8
BMI or W/H ratio 90.0 88.3 88.9 53.3 40.4 42.6
Triglyceride 75.8 76.2 76.1 66.7 51.4 54.0
Blood pressure 92.7 88.7 90.0 70.0 67.8 68.2
Microalbuminuria 64.6 69.2 67.6 86.2 87.8 87.5
IGT, impaired glucose tolerance test.and fasting blood glucose was found to be higher in females than
in males.
The association between cardiovascular risk and the compo-
nents of the metabolic syndrome was calculated (Table 5). High
strength of association was found for HBP with odds ratios with
95% CI of 13.6 (7.13–26.03), 11.97 (5.86–24.45), and 10.5 (5.44–
20.26) for the criteria of IDF, NCEP III, and WHO, respectively. In
addition, when analyzing by sex, the odds ratio for female’s sub-
jects was about two times higher than for male subjects. The waist
circumferences in IDF and NCEP III has cardiovascular risk at odds
ratio with 95% CI of 4.32 (2.42–7.71) and 3.92 (2.21–6.97), respec-
tively. But the BMI or W/H ratio in WHO was associated to lesser
cardiovascular risk than the others at odds ratio with 95% CI of
2.83 (1.52-5–27). Again, when this component was analyzed by
sex, it was found that odds ratio for female subjects were about
two times higher than for male. The high triglyceride (HTG) in
IDF and NCEP III has been associated with cardiovascular risk at
odds ratio with 95% CI of 3.63 (1.9–6.94) and 3.93 (2.07–7.48),
respectively. When this component was analyzed by sex, it was
also found that the odds ratio for male groups was about two times
higher than that for female. HDL was not found to be signiﬁcantly
related to cardiovascular risk for any criterion. The rest of the com-
ponents in each criterion were found to have an odds ratios of 2–3.4. Discussion
In the present study, we found that the components of WC in
IDF and FBG in NCEP III had higher sensitivity and speciﬁcity, mak-
ing themmore suitable to diagnose Mts. The components of HBP in
IDF and NCEP III had predominately the same effects in the female
groups.
A manuscript of the author published in Journal of Diabetes and
its Complications compared three criteria of Mts (WHO, NCEP III,
and IDF) to predict cardiovascular risk. The results of this study
show that IDF criteria were appropriate in predicting cardiovascu-
lar risks in female, whereas NCEP III was more suitable for males.
For the above reasons, the author was interested in analysing each
of components in the different criteria to prove which of each com-
ponent among three criteria was the strongest in predicting cardio-
vascular risk.
Our study used baPWV represented as cardiovascular risks,
since it had some previous evidence-base studies [15,16] showing
correlation between baPWV and a marker of atherosclerotic vascu-
lar damage and cardiovascular risks. Our study is in agreement
with studies [17,18] that the peripheral PWV or arterial stiffness
was the best correlated marker to represent cardiovascular risks.
For prediction of cardiovascular risks through the components
of Mts by each criteria, we observed that the ﬁrst, the component
of HBP, in the three criteria, was signiﬁcantly associated with CVD.
Since this component can directly affect the blood vessels and the
cardiovascular system, it would increase the risk of CVD [19].
Second, the component of WC in the IDF and NCEP III has a
higher association to cardiovascular risk than BMI or W/H ratio
in the WHO, because the WC represents visceral fat, which several
studies have related to an increase in the risk of CVD [20–22].
Additionally, our study has shown that not only the WC of female
group in IDF signiﬁcant associates with CVD risk but also the BMI
or W/H ratio of female group in WHO had the same effects. From
these results, it may be concluded that the WC of female group
in IDF is the strongest predictor of cardiovascular risks, which is
in agreement with a previous study [23]. It is interesting to note
that gender differences in the relationship between Mts and sub-
clinical atherosclerosis have been recently reported. Women
showed a stronger risk factor for carotid atherosclerosis than
men [24,25].
Table 5
Odds ratios with 95% conﬁdence interval for the association between cardiovascular risk and the components of metabolic syndrome according to IDF, NCEP III, and WHO criteria.
Male Female Overall
OR* 95% CI OR* 95% CI OR** 95% CI
IDF
Waist circumference 1.81 0.63–5.23 6.34 3.08–13.05 4.32 2.42–7.71
Triglyceride 6.24 1.42–27.38 3.54 1.67–7.51 3.63 1.9–6.94
HDL 1.69 0.56–5.1 1.22 0.57–2.61 1.37 0.75–2.48
Blood pressure 12.6 3.02–52.47 14.5 6.73–31.14 13.6 7.13–26.03
Fasting blood glucose 1.35 0.29–6.38 2.1 1.03–4.3 1.99 1.06–3.73
NCEP III
Waist circumference 3.83 0.96–15.29 3.97 2.08–7.57 3.92 2.21–6.97
Triglyceride 8.76 2.02–37.93 3.35 1.61–7 3.93 2.07–7.48
HDL 1.62 0.52–4.99 1.25 0.6–2.6 1.35 0.75–2.43
Blood pressure 14.63 2.29–93.59 12.93 5.78–28.92 11.97 5.86–24.45
Fasting blood glucose 1.1 0.19–6.44 2.55 1.18–5.55 2.21 1.11–4.43
WHO
Fasting blood glucose or IGT 3.57 0.8–15.9 2.12 1.03–4.39 2.28 1.2–4.32
BMI or W/H ratio 1.82 0.56–5.92 3.36 1.6–7.08 2.83 1.52–5.27
Triglyceride 2.11 0.58–7.63 2.72 1.32–5.6 2.49 1.36–4.58
Blood pressure 7.24 1.72–30.47 13.3 6.06–29.09 10.5 5.44–20.26
Microalbuminuria 4.43 1.29–15.19 2.33 1.06–5.13 2.83 1.49–5.39
IGT, impaired glucose tolerance test.
* Adjusted for all components of metabolic syndrome in the same criteria including age, LDL, cholesterol, and smoking.
** Adjusted for all components of metabolic syndrome in the same criteria including age, sex, LDL, cholesterol, and smoking.
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(HTG) was signiﬁcantly associated with cardiovascular risk in IDF
and NCEP III, but this was not the case in WHO, consistent with
previous studies [26,27]. The effect of HTG could be a consequence
of increased visceral fat, whose relation to cardiovascular risk has
already been described [20–22]. In the male group, HTG in IDF
has a signiﬁcant association to cardiovascular risk than in the fe-
male group, whereas a previous study has found no such a differ-
ence [27]. This study, however, includes subjects selected from
the general population, rather than subjects having metabolic syn-
drome, as in our case.
We must acknowledge that our study has some limitations.
First, as our study is based on a cross-sectional design, causal rela-
tionships between risk factors and outcomes could not be claimed
at the moment [28]. Additionally, our subjects were predominantly
female, in the middle age group, which might not represent the
general population. Second, our cross-sectional study consisted of
patients at high risk of CVD, since the most of our subjects have
Mts consisting of DM, DLD, and HT, each of which has increased
risk of CVD [25]. Thus, our ﬁnding relates to subjects at increased
risk of both elevated levels of atherosclerosis and cardiovascular
events, and might not be applicable to the general population. Fi-
nally, our study used PWV as representation of CVD risk [15–18],
which is used extensively as a measure of subclinical atherosclero-
sis, and relates to the future risk of clinical cardiovascular events in
Mts patients [15,16]. Additional prospective clinical studies are re-
quired to determine the suitability of each component using differ-
ent Mts criteria in predicting the occurrence of ischemic heart
disease in both males and females.
Our results may be applied in two clinical aspects: First, we
found that the cut off point of WC in IDF, the level of FBG more
than 110 mg/dl and the HBP over than 130/85 mm Hg in female
groups, respectively, were the appropriate components to use for
diagnosis of Mts. Second, we found that the HBP over than 130/
85, cut off point of WC in female group by IDF criteria and HTG
of male group in IDF criteria were the appropriate components to
use for the prediction of cardiovascular risk.
We may summarise that the appropriate components to predict
cardiovascular risks are: high blood pressure and cut off point of
waist circumference in females, as deﬁned by the IDF criterion,
and high triglyceride in males, as deﬁned by the IDF criterion.Acknowledgement
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